OptimizeRx Q2 revenue falls 1% to $13.8M, GAAP EPS loss $(0.24), cuts 2023 outlook.

OptimizeRx Corp

2023-Q2 EPS reported -$0.21 revenue$26,821,076

Revenue $13.8M, down 1% YoY; gross profit $7.8M, down 13%.
GAAP net loss $(4.2)M ($(0.24)/share); non-GAAP net loss $(0.2)M ($(0.01)/share).
Repurchased 526,999 shares at avg $14.27 for $7.5M in Q2.
RWD.AI-enabled business saw 186% YoY growth in H1 2023.
Full-year 2023 revenue guidance cut to mid-$50s to low-$60s million; gross margin 55-59%.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

OptimizeRx Corp reported fiscal year 2023 results: revenue mid-50 to low-60 million dollars.

Period: fiscal year 2023
Revenue: mid-50 to low-60 million dollars
Result: guidance update

Exact text from the filing

Based on first half results, the Company is updating its full year financial outlook for 2023. Revenues are now expected to be in the mid-50 to low-60 million dollar range with a gross margin rate between 55% and 59%.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

OptimizeRx Corp reported quarter ended June 30, 2023 results: net income $(4.2) million, EPS $(0.24).

Period: quarter ended June 30, 2023
Net income: $(4.2) million
EPS: $(0.24)
Result: reported results

Exact text from the filing

Revenue in the second quarter of 2023 decreased 1% to $13.8 million, as compared to $14.0 million in the same year ago period.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

OptimizeRx Corp reported quarter ended June 30, 2023 results: net income $(4.2) million, EPS $(0.24).

Period: quarter ended June 30, 2023
Net income: $(4.2) million
EPS: $(0.24)
Result: reported results

Exact text from the filing

GAAP net loss totaled $(4.2) million or $(0.24) per basic and diluted shares outstanding in the second quarter, as compared to $(3.9) million or $(0.21) during the second quarter of 2022.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

OptimizeRx Corp filing history →

Source: SEC EDGAR

accession 0001213900-23-067012

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.